The short answer
KPV holds no marketing authorisation from the MHRA, EMA or FDA and has not been through regulatory review in any jurisdiction. There is no registered interventional trial programme and no human clinical data, so it is supplied for laboratory research only, with no claim made about inflammation or any condition in any person.
Key facts
- MHRA status
- Not authorised
- EMA status
- Not authorised
- FDA status
- Not approved
- Clinical trials
- None established
- UK supply basis
- Laboratory research only
- Specific risk
- Anti-inflammatory indication language
The position
No regulator has assessed KPV. There is no marketing authorisation in any jurisdiction, no registered interventional trial programme, and no route by which laboratory research material becomes a medicine. It is supplied here on the same basis as everything else in the catalogue.
Why this category's literature is a particular hazard
The published work is anti-inflammatory and includes colitis models, so it is research framed around a disease. That framing makes it unusually easy to slide from reporting a study to implying a treatment, because the vocabulary of the literature is already the vocabulary of an indication. The distance between mice with induced colitis and a person with inflammatory bowel disease is the whole distance that matters.
Research material referenced
KPV 10mg, third-party HPLC tested
What is said here and what is not
Reported: that KPV is the C-terminal tripeptide of alpha-MSH, that studies describe effects on NF-κB signalling and cytokine production in cell culture, and that a 2008 paper reported anti-inflammatory potential in murine colitis. Not said: that it treats, reduces or affects inflammation in any person. The first set is fact about published work; the second would be a therapeutic claim.
The enforcement context
The MHRA opened investigations into UK retailers making therapeutic claims about unregulated peptide products in April 2026. The framework turns on the claim and the intended use rather than the compound, and an anti-inflammatory claim about a research chemical is squarely within what it addresses.
What would change the position
An application to and assessment by the MHRA. For KPV that would first require the clinical development that does not currently exist: no registered trials, no human data, and no defined molecular target.
Frequently asked questions
Is KPV legal in the UK?
It is supplied as a material for laboratory research. It is not a licensed medicine and cannot be prescribed or dispensed.
Why is the anti-inflammatory literature a compliance risk?
Because the vocabulary of the research is already the vocabulary of an indication, which makes sliding from reporting a study to implying a treatment unusually easy.
Are there registered trials?
None established. There is no human clinical data for KPV.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- The Transporter That Explains the TripeptideKPV is a substrate for PepT1, the intestinal di- and tripeptide transporter. That single fact organises almost everything published about this molecule.
- Delete the Transporter and the Effect DisappearsIn PepT1 knockout mice, KPV produced none of the effect it produced in wild-type animals. That is a stronger mechanistic test than any dose-response curve.
- When the Tripeptide Is the Address, Not the CargoRecent work increasingly attaches KPV to something else - a dye, a nanoparticle, a drug carrier - and uses its affinity to reach cells overexpressing PepT1.
- A Second Claim, With a Different MechanismWork from 2000 reported that alpha-MSH and its KPV fragment inhibited Staphylococcus aureus and Candida albicans. That is not the anti-inflammatory claim.
- The Part of the Hormone That Talks to the Receptor Is Not in KPVMelanocortin receptor activation requires the His-Phe-Arg-Trp core, and that tetrapeptide alone is an agonist. KPV is residues 11 to 13 and contains none of it.